EP Patent

EP1618881A1 — Use of non-glucocorticoid steroids for the treatment of muscular dystrophy

Assigned to Santhera Pharmaceuticals Schweiz GmbH · Expires 2006-01-25 · 20y expired

What this patent protects

The invention relates to the therapeutic use of certain classes of steroid compounds for treatment of muscular diseases, in particular muscle diseases caused by mutations in the gene encoding for dystrophin (Duchenne Muscular Dystrophy, DMD, and Becker Muscular Dystrophy, BMD). T…

USPTO Abstract

The invention relates to the therapeutic use of certain classes of steroid compounds for treatment of muscular diseases, in particular muscle diseases caused by mutations in the gene encoding for dystrophin (Duchenne Muscular Dystrophy, DMD, and Becker Muscular Dystrophy, BMD). The steroid compounds increase the levels of the dystrophin-related protein utrophin in cultured human muscle cells derived from donors affected with Duchenne Muscular Dystrophy.

Drugs covered by this patent

Patent Metadata

Patent number
EP1618881A1
Jurisdiction
EP
Classification
—
Expires
2006-01-25
Drug substance claim
No
Drug product claim
No
Assignee
Santhera Pharmaceuticals Schweiz GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.